Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease

Unlike perianal fistula, long‐term outcomes of nonperianal fistulae (NPF) in Crohn's disease (CD) are not clear. We aimed to compare the outcomes of medical and surgical therapies in patients with NPF.

[1]  W. Reinisch,et al.  Burden and outcomes for complex perianal fistulas in Crohn’s disease: Systematic review , 2018, World journal of gastroenterology.

[2]  S. Kedia,et al.  High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India , 2018, Intestinal research.

[3]  A. Amiot,et al.  Anti‐TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) , 2018, Alimentary pharmacology & therapeutics.

[4]  S. Kedia,et al.  Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East , 2017, Inflammatory Intestinal Diseases.

[5]  J. Sosna,et al.  Factors associated with surgery in patients with intra-abdominal fistulizing Crohn's disease , 2016, World journal of gastroenterology.

[6]  V. Yajnik,et al.  Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. , 2016, World journal of gastroenterology.

[7]  A. Amiot,et al.  Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID , 2014, The American Journal of Gastroenterology.

[8]  J. Carvalho,et al.  Squamous cell carcinoma in enterocutaneous fistula associated with Crohn's disease: first case report. , 2014, Journal of Crohn's & colitis.

[9]  G. D'Haens,et al.  Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE , 2013, Alimentary pharmacology & therapeutics.

[10]  J. Gisbert,et al.  Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy. , 2012, Journal of Crohn's & colitis.

[11]  S. Fine.  Adalimumab for the treatment of fistulas in patients with Crohn's disease. , 2011, Inflammatory bowel diseases.

[12]  Norbert Senninger,et al.  Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis , 2011, Journal of Gastrointestinal Surgery.

[13]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[14]  T. Chiba,et al.  The effect of medical treatment on patients with fistulizing Crohn's disease: a retrospective study. , 2008, Internal medicine.

[15]  A. Darzi,et al.  The Risk of Cancer in Patients with Crohn’s Disease , 2007, Diseases of the colon and rectum.

[16]  D. Morton,et al.  Adenocarcinoma of the Small Bowel Arising From a Previous Strictureplasty for Crohn’s Disease: Report of a Case , 2007, Diseases of the colon and rectum.

[17]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[18]  J. Gisbert,et al.  Predictors of response to infliximab in patients with fistulizing Crohn's disease. , 2004, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[19]  J. Connor,et al.  Type of Fistula Determines Response to Infliximab in Patients with Fistulous Crohn's Disease , 2004, American Journal of Gastroenterology.

[20]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[21]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[22]  A. Zinsmeister,et al.  The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. , 2002, Gastroenterology.

[23]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[24]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[25]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[26]  J. Vaillant,et al.  Surgical management of internal fistulas in Crohn's disease. , 1996, Journal of the American College of Surgeons.

[27]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[28]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[29]  B. Schuman.  Adenocarcinoma arising in an excluded loop of ileum. , 1970, The New England journal of medicine.

[30]  W. Bloquiaux.  [Crohn's disease and cancer]. , 1968, Tijdschrift voor gastro-enterologie.